Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.

@article{Reams2003PosttransplantLD,
  title={Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients.},
  author={B. Diane Reams and H. Page McAdams and David N. Howell and Mark P. Steele and Robert Duane Davis and Scott M. Palmer},
  journal={Chest},
  year={2003},
  volume={124 4},
  pages={1242-9}
}
INTRODUCTION Posttransplant lymphoproliferative disorder (PTLD) is a relatively infrequent but devastating complication that occurs after solid-organ transplantation. Although the optimal treatment for this condition is unknown, rituximab, a murine/human chimeric monoclonal antibody, has shown promise in the treatment of PTLD. In this report, we define the incidence, clinical features at presentation, and response to treatment of all cases of PTLD observed at our institution over a 10-year… CONTINUE READING